Evan David Seigerman
Stock Analyst at BMO Capital
(1.93)
# 3,087
Out of 4,910 analysts
45
Total ratings
39.02%
Success rate
-7.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
REPL Replimune Group | Downgrades: Underperform | $27 → $2 | $3.17 | -36.91% | 4 | Jul 23, 2025 | |
NGNE Neurogene | Maintains: Outperform | $22 → $26 | $22.67 | +14.69% | 2 | Jun 12, 2025 | |
REGN Regeneron Pharmaceuticals | Maintains: Outperform | $800 → $600 | $570.60 | +5.15% | 7 | Jun 2, 2025 | |
MRUS Merus | Maintains: Outperform | $96 → $110 | $66.25 | +66.04% | 1 | May 23, 2025 | |
ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $23.44 | +19.45% | 1 | May 19, 2025 | |
ARVN Arvinas | Maintains: Outperform | $20 → $10 | $7.94 | +26.02% | 1 | May 5, 2025 | |
NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $70.58 | -9.32% | 6 | Apr 17, 2025 | |
MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $84.11 | +14.14% | 4 | Feb 5, 2025 | |
ABBV AbbVie | Maintains: Outperform | $208 → $215 | $191.45 | +12.30% | 7 | Feb 3, 2025 | |
AMGN Amgen | Maintains: Outperform | $362 → $346 | $308.97 | +11.99% | 4 | Jan 29, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $18.21 | +449.06% | 2 | Jun 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $25.32 | +42.18% | 4 | May 2, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $7.08 | -57.63% | 1 | May 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $806.80 | -50.92% | 1 | Sep 6, 2022 |
Replimune Group
Jul 23, 2025
Downgrades: Underperform
Price Target: $27 → $2
Current: $3.17
Upside: -36.91%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $22.67
Upside: +14.69%
Regeneron Pharmaceuticals
Jun 2, 2025
Maintains: Outperform
Price Target: $800 → $600
Current: $570.60
Upside: +5.15%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $66.25
Upside: +66.04%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $23.44
Upside: +19.45%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $7.94
Upside: +26.02%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $70.58
Upside: -9.32%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $84.11
Upside: +14.14%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $191.45
Upside: +12.30%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $308.97
Upside: +11.99%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $18.21
Upside: +449.06%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.32
Upside: +42.18%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $7.08
Upside: -57.63%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $806.80
Upside: -50.92%